The aim of this study is to explore the effectiveness of semaglutide, one of the GLP-1 RAs, in combination with a lifestyle intervention in promoting weight loss and improving metabolic outcomes among individuals with obesity or overweight and SMI who are residing in a psychiatric setting. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.